Efektivitas Antibiotik Pada Pasien Pneumonia Covid-19 : Studi Observasional

Syah, Farid Zulkarnain Nur and Rahem, Abdul and Purnamayanti, Anita and Karunia, Rella Indah (2022) Efektivitas Antibiotik Pada Pasien Pneumonia Covid-19 : Studi Observasional. Jurnal Ilmiah Ibnu Sina (JIIS): Ilmu Farmasi dan Kesehatan, 7 (2). pp. 241-250. ISSN 2502-647X; e-ISSN: 2503-1902

PDF Farid Zulkarnain_A. Rahem_Anita Purnamayanti_878-Article Text-4210-1-10-20221031.pdf Download (947kB)

Abstract

COVID-19 telah menjadi pandemi dan menyebabkan kematian diseluruh dunia. Penggunaan antibiotik empiris pada kasus Pneumonia COVID-19 berisiko memicu resistensi bakteri. Tujuan penelitian untuk menganalisis efektivitas penggunaan antibiotik pada kasus Pneumonia COVID-19. Penelitian observasional dengan arah pengambilan data secara retrospektif periode Juni 2021 hingga Agustus 2021. Subjek penelitian adalah subjek terkonfirmasi Pneumonia COVID- 19, dibuktikan dengan hasil CT scan dada dan PCR. Total subjek penelitian 111 subjek yang mendapatkan antibiotik azitromisin (n = 42) atau levofloksasin (n = 69). Tidak terdapat perbedaan bermakna antara kondisi klinis awal masuk RS pada subjek yang mendapat azitromisin dengan subjek yang memperoleh levofloksasin (p=0,098) berdasarkan skor WHO clinical progression scale. Terdapat perbedaan bermakna antara azitromisin dengan levofloksasin untuk lama terapi (p = 0,000) dan lama rawat inap (p = 0,004). Terdapat perbedaan bermakna (p = 0,006) kondisi klinis berdasarkan selisih skor WHO clinical progression scale sebelum dan sesudah menggunakan azitromisin, namun, tidak terdapat perbedaan bermakna (p = 0,114) kondisi klinis sebelum dan sesudah menggunakan levofloksasin. Tidak terdapat perbedaan angka kematian yang bermakna (p = 0,275) pada kedua jenis antibiotik. Kematian subjek tidak dipengaruhi oleh jenis kelamin, usia lanjut ( > 65 tahun), dan komorbid penyakit. Azitromisin lebih efektif memperbaiki kondisi klinis subjek Pneumonia COVID-19 dibandingkan dengan levofloksasin. COVID-19 has become a deadly pandemic worldwide. The use of empiric antibiotics in cases of COVID-19 pneumonia has the risk of triggering bacterial resistance. The purpose of the study was to analyze the use of antibiotics used in cases of COVID-19 pneumonia. The design of the study was an observational study conducted retrospectively from June 2021 to August 2021. The subjects of the study were patients with confirmed COVID-19 pneumonia, as diagnosed by the doctor based on the results of a chest CT scan and PCR. The total number of research subjects was 111. The antibiotics used were azithromycin (n = 42) and levofloxacin (n = 69). There was no significant difference between the initial clinical condition of hospital admission in subjects receiving azithromycin and subjects receiving levofloxacin (p=0.098) based on the WHO clinical progression scale score. There was a significant difference between azithromycin and levofloxacin for the length of therapy (p = 0.000) and length of hospitalization (p = 0.004). There was a significant difference (p = 0.006) in clinical conditions based on WHO clinical progression scale scores before and after using azithromycin. There was no significant difference (p = 0.114) in clinical conditions before and after using levofloxacin. There was no significant difference in mortality (p = 0.275) between the two types of antibiotics. Subject mortality was not affected by gender, advanced age (> 65 years), and comorbid disease. Azithromycin is more effective in improving the clinical condition of patients with COVID-19 pneumonia compared to levofloxacin.

Item Type:	Article
Uncontrolled Keywords:	Efektivitas, Azitromisin, Levofloksasin, Pneumonia COVID-19
Subjects:	R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Pharmacy > Department of Pharmacy
Depositing User:	Ester Sri W. 196039
Date Deposited:	02 Jan 2023 05:52
Last Modified:	02 Jan 2023 05:52
URI:	http://repository.ubaya.ac.id/id/eprint/43031

Actions (login required)

View Item